

Tiwari, Ritika ORCID logoORCID:

<https://orcid.org/0000-0002-5078-8989>, Amien, Aqeelah, Visser, Willem I. and Chikte, Usuf (2022) Counting dermatologists in South Africa: number, distribution and requirement. British Journal of Dermatology, 187 (2). pp. 248-250.

Downloaded from: <https://ray.yorks.j.ac.uk/id/eprint/8536/>

The version presented here may differ from the published version or version of record. If you intend to cite from the work you are advised to consult the publisher's version:

<https://doi.org/10.1111/bjd.21036>

Research at York St John (RaY) is an institutional repository. It supports the principles of open access by making the research outputs of the University available in digital form. Copyright of the items stored in RaY reside with the authors and/or other copyright owners. Users may access full text items free of charge, and may download a copy for private study or non-commercial research. For further reuse terms, see licence terms governing individual outputs. [Institutional Repository Policy Statement](#)

RaY

Research at the University of York St John

For more information please contact RaY at ray@yorks.j.ac.uk

¹Wayne State University School of Medicine, Detroit, MI, USA; ²Department of Dermatology, Henry Ford Health System, Detroit, MI, USA; and ³Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA

Correspondence: Jesse Veenstra.

Email: jveenst1@hfhs.org

References

- Balagula Y, Dusza SW, Zampella J et al. Early-onset mycosis fungoides among African American women: a single-institution study. *J Am Acad Dermatol* 2014; **71**:597–8.
- Huang AH, Kwatra SG, Khanna R et al. Racial disparities in the clinical presentation and prognosis of patients with mycosis fungoides. *J Natl Med Assoc* 2019; **111**:633–9.
- Nath SK, Yu JB, Wilson LD. Poorer prognosis of African-American patients with mycosis fungoides: an analysis of the SEER dataset, 1988 to 2008. *Clin Lymphoma Myeloma Leuk* 2014; **14**:419–23.
- Sun G, Berthelot C, Li Y et al. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. *J Am Acad Dermatol* 2009; **60**:231–5.
- Geller S, Lebowitz E, Pulitzer MP et al. Outcomes and prognostic factors in African American and black patients with mycosis fungoides and Sézary syndrome: retrospective analysis of 157 patients from a referral cancer center. *J Am Acad Dermatol* 2020; **83**:430–9.
- Buechler CR, Sagher E, Tisack A et al. Contribution of socioeconomic risk factors within a diverse mycosis fungoides cohort from Detroit, MI. *J Am Acad Dermatol* 2022; in press; doi: <https://doi.org/10.1016/j.jaad.2021.12.016>.
- Emran AA, Gallagher SJ, Tiffen JC, Hersey P. Sex bias of females in survival from cancer and infections. Is X the answer? *Br J Cancer* 2021; **124**:1184–6.
- Salas LA, Peres LC, Thayer ZM et al. A transdisciplinary approach to understand the epigenetic basis of race/ethnicity health disparities. *Epigenomics* 2021; **13**:1761–70.

Funding sources: this work was in part supported by the William Clay Ford Jr and Lisa V. Ford Foundation. Funds for statistical support were provided through the Graduate Medical Education office at Henry Ford Hospital. The funders had no role in the study design, data collection, data analysis, manuscript preparation or publication decisions.

Conflicts of interest: the authors declare they have no conflicts of interest.

Data availability: the data that support the findings of this study are available from the corresponding author upon reasonable request.

Counting dermatologists in South Africa: number, distribution and requirement

DOI: 10.1111/bjd.21036

DEAR EDITOR, Dermatological diseases continue to contribute significantly to the burden of disease worldwide, affecting all populations and age groups. Skin disease has been considered the fourth leading cause of nonfatal disease globally.¹ Low-socioeconomic settings reflect a high prevalence of

dermatological disease, ranging from 50% to 80% of the population.² Despite this high burden of disease in low- and middle-income countries, a shortage of dermatologists is reported for most African countries (Namibia 0.8, Ghana 1.1, South Africa 3, Botswana 3.3 dermatologists per million population) in comparison with the rest of the world (UK 10, USA 36, Germany 65 dermatologists per million population). In Africa, < 1 dermatologist is available per million population, with the majority practising in urban areas.³ The paucity of dermatologists is concerning, as dermatological disease has substantial impact on long-term morbidity.²

This analysis utilized the Health Professions Council of South Africa (HPCSA) database (from 2000 to 2019) with the variables: (i) category of health personnel (specialty – dermatology); (ii) geographical location; (iii) population category; and (iv) sex. In this article, we have used the term ‘population group’ in line with the definitions in the Population Registration Act (Act No. 30 of 1950),⁴ which previously classified South African citizens into four major population categories: ‘white’, ‘coloured’, ‘Indian’ and ‘black’. Although the legislation was repealed in 1991, population categories are still used in reporting in sectors such as the Department of Higher Education. Racialized data continue to be used in monitoring the redress in the education and training of dermatologists who were previously denied access to such training due to legislation. National databases such as Statistics South Africa and the HPCSA also segregate their data based on these same population groups.

Assessment of privatization of dermatology practices was undertaken by geographically mapping each dermatology private practice based on their area codes. This was compared with province-wide HPCSA registrations and with data procured from the General Household Survey regarding the medically insured population per province in 2019.⁵ Ethical approval was obtained from the Stellenbosch University Health Research Ethics Committee (reference no. X21/05/010).

The data were analysed using the SPSS version 22.0 (IBM, Armonk, NY, USA). For the analysis of training capacity and the supply pipeline, data were collected from the Colleges of Medicine of South Africa and the academic heads of dermatology divisions across South African universities. The deficit of dermatologists was forecasted using the disability-adjusted life-year (DALY).⁶ A DALY represents a lost year of ‘healthy’ life, thus measuring burden of disease. The DALY load per dermatologist was 1254 for SA (2019) (Figure 1), which is lower than in other African countries such as 1313 for Botswana (2021) and 6085 for Namibia (2021), but higher than in developed countries, such as 814 for the UK (2012) and 211 for the USA (2015).

In total 264 dermatologists were registered (in nine provinces), of whom 208 were aged ≤65 years as registered with the HPCSA in December 2019, amounting to 4.4 practising dermatologists (3.5 for dermatologists aged ≤65 years) per million population. In the public sector the ratio is 1.2 dermatologists and in the private sector 20.1 dermatologists per million population. There is equal distribution of male and female dermatologists (50% each). Most dermatologists are




Figure 1 Status of dermatologists in South Africa, 2019 (dermatologists registered aged ≤ 65 years). Privatization was assessed by geographically mapping each dermatology private practice based on the area codes of their phone numbers. The numbers of dermatologists operating within the private sector were divided by the total registrations as per the Health Professions Council of South Africa (2019). DALY, disability-adjusted life-year.

practising in the more densely populated and urbanized areas, with 78% operating in the private sector. The majority (50%) of dermatologists identified themselves as white, followed by black (25%), Asian (18%) and coloured (3%), and 4% were unknown. Of the current trainee dermatologists, 49 are paid registrars who are state funded and 15 are unpaid supernumerary registrars (non-South African registrars).

The aim in South Africa has been not to increase the number of dermatologists but to provide equitable access to dermatology services in the least performing provinces (high DALY load per dermatologist) and increase the required number of dermatologists to the levels in the better performing provinces (low DALY load per dermatologist) to achieve horizontal equity. The national shortfall for 2030 was projected to be (at least) within the range of 54–95 dermatologists.

The lack of dermatologists affects the public sector and less urbanized provinces to a greater degree. Among medical specialists, a wage differential of up to two times exists, which contributes to the South African dermatology workforce being inequitably distributed across provinces and public and private sectors. Thus, additional rural pay may incentivize retention of dermatologists in rural areas. Additional training of general practitioners and nurses in dermatological care and implementation of teledermatology programmes is also recommended. With enhanced and equitable implementation of human

resources for health planning,⁷ improved access to dermatological care may be achieved.

Acknowledgments: We would like to thank the HPCSA for providing their database for use.

Ritika Tiwari ,¹ Aqeelah Amien ,² Willem I. Visser ³ and Usuf Chikte ¹

¹Division of Health Systems and Public Health, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; ²Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; and ³Division of Dermatology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
 Email: ritika.t.za@gmail.com

References

- 1 Flohr C, Hay R. Putting the burden of skin diseases on the global map. *Br J Dermatol* 2021; **184**:189–90.
- 2 Hay RJ, Fuller LC. The assessment of dermatological needs in resource-poor regions. *Int J Dermatol* 2011; **50**:552–7.
- 3 Mosam A, Todd G. Dermatology training in Africa: successes and challenges. *Dermatol Clin* 2021; **39**:57–71.

- 4 Seekings J. The continuing salience of race: discrimination and diversity in South Africa. *J Contemp Afr Studies* 2008; **26**:1–25. <https://www.tandfonline.com/doi/abs/10.1080/02589000701782612>
- 5 Statistics South Africa. General household survey 2019. Available at: <http://www.statssa.gov.za/publications/P0318/P03182019.pdf> (last accessed 5 April 2022).
- 6 Tiwari R, Bhayat A, Chikte U. Forecasting for the need of dentists and specialists in South Africa until 2030. *PLOS ONE* 2021; **16**: e0251238.
- 7 National Department of Health. 2030 Human Resources for Health Strategy: Investing in the Health Workforce for Universal Health Coverage. Pretoria: Government Printers, 2020.

Funding sources: none.

Conflicts of interest: the authors declare they have no conflicts of interest.

Data availability statement: The data that supports the findings of this study are available in the supplementary material of this article.

Hidradenitis suppurativa may impact clothing patterns even in patients with mild disease and symptoms: an observational study

DOI: 10.1111/bjd.21035

DEAR EDITOR, Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by a fragile follicular unit.¹ Pressure and friction, secondary to clothing, can potentially cause the follicular unit to rupture and exacerbate a patient's HS.² However, current literature investigating the effect of clothing on HS is limited to anecdotal reports and limited

quantitative data.^{2,3} Moreover, clinical guidelines currently lack evidence to support clothing recommendations.⁴ Disease and symptom severity in a patient with HS may provide a useful clinical tool to identify patients at risk for clothing-based disease exacerbations. Recognition of at-risk patients may help implement practical patient clothing changes to decrease HS burden.

Patients with a clinical diagnosis of HS (International Classification of Diseases 10th Revision code 73.2) ($n = 153$) were recruited by mail ($n = 123$) and clinic ($n = 30$) between June and September 2018 after institutional review board approval was obtained, and 67 surveys were completed (mail $n = 40$, clinic $n = 27$). Differences in mean disease severity and number of painful nodules were compared with responses related to clothing patterns. Data were analysed using SAS software version 9.4 (IBM, Armonk, NY, USA). Differences in group comparisons by mean score were analysed using ANOVA and Student *t*-test. Differences in the percentage of respondents were analysed using χ^2 -tests. Patients used a validated self-assessment tool to report disease severity using the Hurley staging system.⁵ Patients self-reported their number of painful nodules, severity of scarring, frequency of itch, burning and leakage.

Respondents (mean age 39 years, 90% female, 57% African American) had comparable demographics to nonresponders (mean age 36 years, 80% female, 38% African American). Respondents had an average body mass index of 35.7 kg m^{-2} , 56% had a family history of HS, 28% currently smoked, 22% had Hurley stage 1, 35% had Hurley stage 2 and 43% had Hurley stage 3 disease severity. Overall, respondents reported that tight clothing (76%) and mechanical stress (i.e. pressure on skin from clothing or belts) (73%) worsened their

Table 1 Hidradenitis suppurativa (HS) sample characteristics

	Mean score	Tight clothing worsened HS	Mechanical stretch worsened HS
Disease severity per Hurley score	1	71%	82%
	2	71%	71%
	3	81%	85%
Number of body regions with HS	< 3	38% ^a	38% ^d
	≥ 3	85% ^a	81% ^d
Number of painful nodules	≤ 5	57% ^b	62% ^e
	> 5	89% ^b	89% ^e
Severity of scarring associated with HS	None to mild	73%	64%
	Moderate	72%	66%
	Severe	81%	85%
Frequency of itch associated with HS	Daily	83%	80%
	< Daily	66%	64%
Frequency of leakage associated with HS	Daily	90% ^c	93% ^f
	< Daily	59% ^c	55% ^f
Frequency of burning associated with HS	≤ 1–2 per month	73%	74%
	≥ 1–2 per week	81%	73%

The data are presented as the percentage of respondents. P-values represent χ^2 -tests of independence between an indicator for each HS symptom category and a clothing factor. P-values are statistically significant at a threshold of 5%. Significant differences were identified between values indicated with the same superscript letter.

THE OPPORTUNITY FOR COMPLETE, FAST AND LASTING SKIN CLEARANCE^{1,2}

68.2% achieved PASI 100 at Week 16[†]

75.9% of patients achieved PASI 75 at Week 4[†]

82% of week 16 PASI 100 responders maintained this response up to 3 years²

BIMZELX was well tolerated, the most frequently reported adverse reactions were: upper respiratory tract infections (14.5%, 14.6%, in plaque psoriasis (Pso), and psoriatic arthritis (PsA) respectively) and oral candidiasis (7.3%, 2.3% in Pso, and PsA respectively). Other common reported adverse reactions include Tinea infections, Ear infections, Herpes simplex infections, Oropharyngeal candidiasis, Gastroenteritis, Folliculitis, Headache, Rash, Dermatitis, Eczema, Acne, Injection site reactions, and Fatigue.

Please refer to the SmPC for further information.¹

Challenge expectations in plaque psoriasis^{1,2}

Visit [Bimzelx.co.uk](https://bimzelx.co.uk) to discover more.

This site contains promotional information on UCB products.



Stay connected with UCB by
scanning the QR code and set
your digital preferences.



Use this QR code to
access [Bimzelx.co.uk](https://bimzelx.co.uk)

This is a promotional
UCB website

Footnotes: [†]co-primary endpoints PASI 90 and IGA 0/1 at Week 16

Pso - Plaque Psoriasis; PsA - Psoriatic Arthritis

BIMZELX[®] (Bimekizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Please refer to the SmPC for further information.¹

PRESCRIBING INFORMATION FOR HCP'S IN GREAT BRITAIN

BIMZELX[®] ▼ (Bimekizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; and for active psoriasis arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs), alone or in combination with methotrexate.¹ (Please consult the Summary of Product Characteristics (SmPC) before prescribing).

Active Ingredient: Bimekizumab – solution for injection in pre-filled syringe or pre-filled pen: 160 mg of bimekizumab in 1 mL of solution (160mg/mL). **Indications:** Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Alone or in combination with methotrexate, for active psoriatic arthritis in adults who have had an inadequate response or intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs). Adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Dosage and Administration: Should be initiated and supervised by a physician experienced in the diagnosis and treatment of conditions for which Bimzelx is indicated. **Recommended dose:** Plaque Psoriasis: 320 mg (given as two subcutaneous injections of 160 mg each) at week 0, 4, 8, 12, 16 and every 8 weeks thereafter. Psoriatic arthritis: 160 mg (given as 1 subcutaneous injection of 160 mg) every 4 weeks. For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, the recommended dose is the same as for plaque psoriasis. After 16 weeks, regular assessment of efficacy is recommended and if a sufficient clinical response in joints cannot be maintained, a switch to 160 mg every 4 weeks can be considered. Axial spondyloarthritis (nr-axSpA and AS): 160 mg (given as 1 subcutaneous injection) every 4 weeks. For patients with plaque psoriasis (including psoriatic arthritis with coexistent moderate to severe psoriasis) and a body weight ≥ 120 kg who did not achieve complete skin clearance at week 16, 320 mg every 4 weeks after week 16 may further improve treatment response. Consider discontinuing if no improvement by 16 weeks of treatment. Renal or hepatic impairment: No dose adjustment needed. Elderly:

No dose adjustment needed. Administer by subcutaneous injection to thigh, abdomen or upper arm. Rotate injection sites and do not inject into psoriatic plaques or skin that is tender, bruised, erythematous or indurated. Do not shake pre-filled syringe or pre-filled pen. Patients may be trained to self-inject. **Contraindications:** Hypersensitivity to bimekizumab or any excipient; Clinically important active infections (e.g. active tuberculosis). **Warnings and Precautions:** Record name and batch number of administered product. **Infection:** Bimekizumab may increase the risk of infections e.g. upper respiratory tract infections, oral candidiasis. Caution when considering use in patients with a chronic infection or a history of recurrent infection. Must not be initiated if any clinically important active infection until infection resolves or is adequately treated. Advise patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops an infection, the patient should be carefully monitored. If the infection becomes serious or is not responding to standard therapy do not administer bimekizumab until infection resolves. **TB:** Evaluate for TB infection prior to initiating bimekizumab – do not give if active TB. While on bimekizumab, monitor for signs and symptoms of active TB. Consider anti-TB therapy prior to bimekizumab initiation if past history of latent or active TB in whom adequate treatment course cannot be confirmed. **Inflammatory bowel disease:** Bimekizumab is not recommended in patients with inflammatory bowel disease. Cases of new or exacerbations of inflammatory bowel disease have been reported. If inflammatory bowel disease signs/symptoms develop or patient experiences exacerbation of pre-existing inflammatory bowel disease, discontinue bimekizumab and initiate medical management. **Hypersensitivity:** Serious hypersensitivity reactions including anaphylactic reactions have been observed with IL-17 inhibitors. If a serious hypersensitivity reaction occurs, discontinue immediately and treat. **Vaccinations:** Complete all age appropriate immunisations prior to bimekizumab initiation. Do not give live vaccines to bimekizumab patients. Patients may receive inactivated or non-live vaccinations. **Interactions:** A clinically relevant effect on CYP450 substrates with a narrow therapeutic index in which the dose is individually adjusted e.g. warfarin, cannot be excluded. Therapeutic monitoring should be considered. **Fertility, pregnancy and lactation:** Women of child-bearing potential should use an effective method of contraception during treatment and for at

least 17 weeks after treatment. Avoid use of bimekizumab during pregnancy. It is unknown whether bimekizumab is excreted in human milk, hence a risk to the newborn/infant cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Bimzelx therapy. No data available on human fertility. **Driving and use of machines:** No or negligible influence on ability to drive and use machines. **Adverse Effects:** Refer to SmPC for full information. Very Common ($\geq 1/10$): upper respiratory tract infection; Common ($\geq 1/100$ to $< 1/10$): oral candidiasis, tinea infections, ear infections, herpes simplex infections, oropharyngeal candidiasis, gastroenteritis, folliculitis; headache, rash, dermatitis and eczema, acne, injection site reactions, fatigue; Uncommon ($\geq 1/1,000$ to $< 1/100$): mucosal and cutaneous candidiasis (including oesophageal candidiasis), conjunctivitis, neutropenia, inflammatory bowel disease. Storage precautions: Store in a refrigerator (2°C – 8°C), do not freeze. Keep in outer carton to protect from light. Bimzelx can be kept at up to 25°C for a single period of maximum 25 days with protection from light. Product should be discarded after this period or by the expiry date, whichever occurs first.

Legal Category: POM

Marketing Authorisation Numbers: PLGB 00039/0802 (Pre-filled Syringe), PLGB 00039/0803 (Pre-filled Pen).

UK NHS Costs: £2,443 per pack of 2 pre-filled syringes or pens of 160 mg each.

Marketing Authorisation Holder: UCB Pharma Ltd, 208 Bath Road, Slough, Berkshire, SL1 3WE, United Kingdom.

Further information is available from: UCB Pharma Ltd, 208 Bath Road, Slough, Berkshire, SL1 3WE. Tel: 0800 2793177 Email: ucbcares.uk@ucb.com

Date of Revision: August 2023 (GB-P-BK-AS-2300047)

Bimzelx is a registered trademark.

Adverse events should be reported.

Reporting forms and information can be found at <http://www.mhra.gov.uk/yellowcard>. Adverse events should also be reported to UCB Pharma Ltd at ucbcares.uk@ucb.com or 0800 2793177.

References: 1. BIMZELX (bimekizumab) SmPC. Available at: <https://www.medicines.org.uk/emc/product/12834/smcp>. Accessed September 2023 2. Strober et al. [BE BRIGHT open label extension] Br J Dermatol. 2023. 188(6): 749-759.

GB-BK-2300081 Date of preparation: September 2023.

© UCB Biopharma SRL, 2023. All rights reserved.

BIMZELX[®] is a registered trademark of the UCB Group of Companies.



Inspired by patients.
Driven by science.

Design code 0001